HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Helen Torley, President and Chief Executive Officer of Halozyme Therapeutics, Inc.

“Halozyme delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels.”

Helen Torley, President and Chief Executive Officer of Halozyme Therapeutics, Inc.

“In and post the quarter, we have achieved multiple milestones that expand our opportunity and diversify our revenue. During the quarter, we expanded our agreements with argenx and Incyte to include additional targets to be evaluated with ENHANZE. In October, we also signed an expanded agreement with Johnson & Johnson for one additional target. Three ENHANZE programs, one each with Pfizer, Incyte and argenx advanced into Phase 1 clinical development, bringing our total products in development to twelve.”

Helen Torley, President and Chief Executive Officer of Halozyme Therapeutics, Inc.

“In October, we also achieved an important victory in protecting our intellectual property. The Dutch specialized patent court found that Merck is infringing one of our MDASE patents and granted an injunction prohibiting the launch of Keytruda Qlex in multiple European markets. Our commitment to protecting the value of our innovations, growing royalties, continued partner expansion and growing pipeline demonstrates the power of Halozyme's compounding platform engine and positions us to deliver durable revenue well into the next decade.”

Darren Snellgrove, Executive Vice President and Chief Financial Officer of Halozyme Therapeutics, Inc.

“Based on our strong financial performance this quarter, we are pleased to be able to raise our guidance for the full year 2026. We also further strengthened our financial position with the successful completion of our $1.5 billion convertible notes, which enhances our flexibility to execute our disciplined capital allocation strategy. We completed $400 million in share repurchases this year while continuing to invest in our highest-return organic opportunities and maintaining a clear path to retire our remaining 2027 and 2028 notes at maturity. With our strong cash generation, we remain focused on capital deployment to maximize long-term value creation.”